Follicular lymphoma (FL) is a systemic neoplasm of the lymphoid tissue displaying germinal
centre (GC) B cell differentiation. FL represents~ 5% of all haematological neoplasms and …

Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …

Background Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone) are the standard treatment for aggressive B-cell non-Hodgkin …

Diagnosis should be based on a surgical specimen/excisional lymph node (LN) biopsy.
Core biopsies should only be carried out in patients without easily accessible LNs (eg …

PURPOSE The PRIMA study (ClinicalTrials. gov identifier: NCT00140582) established that 2
years of rituximab maintenance after first-line immunochemotherapy significantly improved …

Patients with follicular lymphoma (FL) frequently require multiple treatments during their
disease course; however, survival based on lines of treatment remains poorly described in …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

PURPOSE We compared 2 years of rituximab maintenance (RM) with a response-adapted
postinduction approach in patients with follicular lymphoma who responded to induction …

Background Histological transformation of follicular lymphoma to aggressive lymphoma is a
serious event with a substantial effect on patient outcome. The aim of the Aristotle study was …

Purpose: To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in
relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least …